13D Filing: Levin Capital Strategies and Fluidigm Corp (FLDM)

Page 11 of 21

Page 11 of 21 – SEC Filing


The following constitutes
the Schedule 13D filed by the undersigned (the “Schedule 13D”). The Reporting Persons (as defined below) remain passive
investors in the Issuer (as defined below) and are filing the Schedule 13D as a result of acquiring over 20% of the outstanding
Shares (as defined below) of the Issuer.

ITEM 1. SECURITY AND ISSUER.

This statement relates
to the common stock, par value $0.001 per share (the “Shares”), of Fluidigm Corporation, a Delaware corporation (the
“Issuer”). The address of the principal executive offices of the Issuer is 7000 Shoreline Court, Suite 100, South San
Francisco, California 94080.

ITEM 2. IDENTITY AND BACKGROUND.
(a) This statement is filed by:
(i) Levin Capital Strategies, L.P., a Delaware limited partnership (“LCS”),
(ii) Levin Capital Strategies GP, LLC, a Delaware limited liability company (“LCS GP”),
(iii) Levin Capital Trilogy Master Fund, Ltd., a Cayman Islands exempt company (“Trilogy”),
(iv) LCS, LLC, a Delaware limited liability company (“LCSL”),
(v) Levcap Alternative Fund, L.P., a Delaware limited partnership (“Levcap”),
(vi) LCS Event Partners, LLC, a Delaware limited liability company (“LCSEP”),
(vii) Safinia Partners, L.P., a Delaware limited partnership (“Safinia”),
(viii) LCS L/S, LLC, a Delaware limited liability company (“LCSLS”), and
(ix) John A. Levin, a U.S. citizen (“Mr. Levin”).

Each of the foregoing
is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Each of the Reporting
Persons is party to that certain Joint Filing Agreement, as further described in Item 6. Accordingly, the Reporting Persons are
hereby filing a joint Schedule 13D.

Set forth on Appendix
A annexed hereto (“Appendix A”) is the name and present principal business, occupation or employment and the name,
principal business and address of any corporation or other organization in which such employment is conducted of the directors
of Trilogy. Trilogy does not have any executive officers.

(b)
The address of the principal executive office of each of the Reporting Persons is: 595 Madison Avenue, 17th Floor, New York,
New York 10022.

(c)
The principal business of LCS is acting as the investment advisor to Trilogy, Levcap, Safinia and certain managed accounts
and as a sub-investment advisor to certain other investment companies, as further described in Item 5. The principal business of
LCS GP is acting as the general partner of LCS. The principal business of Trilogy, Levcap and Safinia is investing in securities.
The principal business of LCSL is acting as the general partner to Trilogy. The principal business of LCSEP is acting as the general
partner to Levcap. The principal business of LCSLS is acting as the general partner to Safinia. The principal business of Mr. Levin
is acting as the Chief Executive Officer of LCS and the managing member of each of LCSL, LCSEP and LCSLS.

11

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 11 of 21